Pharmaceutical company Mankind Pharma Ltd. was established in 1991 and has been in business for 33 years. The business creates and produces a wide variety of pharmaceutical formulations for both acute and long-term therapeutic sectors. Additionally, it is well known in India for its consumer healthcare goods, particularly those marketed under the Prega News and Manforce brands. Among other things, its formulations brand addresses respiratory, cardiovascular, gastrointestinal, and anti-diabetic concerns.
The firm raised Rs 4,326 crore through its IPO, making it the greatest in a single year and the largest by a pharmaceutical company since Gland Pharma raised Rs 6,480 crore through its IPO in 2020. market | 10:00 AM IST, May 9, 2023. On Tuesday, May 9, the Mankind Pharma shares made a good launch on the NSE and BSE stock exchanges.
97% of Mankind Pharma’s revenues come from the domestic market, making India the primary market for the company. The company brings in more than Rs. 7,700 crore in annual sales and has more than 22,000 employees on its payroll. Over 600 scientists work at Mankind Pharma’s R&D facility, where 54 ANDAs have previously been submitted. The business also has one of the biggest medical representative distribution networks in the Indian pharmaceutical industry. In the recent years, it has won a number of accolades.
Who is the Father of Pharma?
The father of Indian pharmacy education is Mahadeva Lal Schroff.
Who is the Mother of Pharma?
The first woman chemist in the United States was Elizabeth Gooking Greenleaf. She was a mother to twelve children and is regarded as the founder of pharmacy. In 1727, Elizabeth established her own apothecary business in Boston.
Who is the Biggest Pharmacist in India?
Since April 2009, Dr. Murtaza Khorakiwala has served as managing director of the Indian company Wockhardt Limited. The nation’s top research-based healthcare company, Wockhardt, has relevance in the industries of pharmaceuticals, biotechnology, and a network of cutting-edge Super Speciality Hospitals.
Which is the Largest Pharma city?
The biggest integrated pharmaceutical cluster in the world, Hyderabad Pharma City (HPC) is located in Hyderabad and is focused on R&D and manufacturing. Because of the cluster’s importance on the national and international levels, the Government of India has designated it as a National Investment and Manufacturing Zone (NIMZ).
Who is the Pharma king of the world?
Dillip Shanghvi’s THE KING OF THE PHARMACEUTICAL WORLD (The Money Makers) Kindle Edition.
Who is the Pharma queen of the world?
The executive director of Emcure Pharmaceuticals is Namita Thapar. An international pharmaceutical corporation with its headquarters in Pune, Maharashtra, is called Emcure Pharmaceuticals.
What is the Rank of Mankind Pharma in India?
Based on total sales, ManKind Pharma is the tenth-largest pharmaceutical firm in India.
What is the highlight of the IPO issues of Mankind Pharma Ltd
The IPO will involve the issuance of 4,00,58, 844 shares (400.59 lakh shares), wholly through an offer for sale (OFS) by the existing shareholders of the company, according to the Draught Red Herring Prospectus (DRHP) submitted with SEBI. The stock will be listed on the BSE and the NSE after the IPO, which will take place via the book-built approach.
Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India, and JP Morgan India will manage the issuance. KFIN Technologies will serve as the issue’s registrar.
The promoter group, along with some of the/ early private equity and other institutional investors, would be the selling shareholders in the OFS. Here is a list of shareholders who are withdrawing a portion of their ownership through the OFS.
| Name of Seller in OFS | Status of seller in OFS | Maximum Shares to be sold |
| Ramesh Juneja | Promoter shareholder | 37,05,443 shares |
| Rajeev Juneja | Promoter shareholder | 35,05,149 shares |
| Sheetal Arora | Promoter shareholder | 28,04,119 shares |
| Cairnhill CIPEF Limited | Investor shareholder | 174,05,559 shares |
| Cairnhill CGPE Limited | Investor shareholder | 26,23,863 shares |
| Beige Limited | Investor shareholder | 99,64,711 shares |
| Link Investment Trust | Investor shareholder | 50,000 shares |
Key dates for Mankind Pharma Ltd IPO and How to apply?
The issue is available for subscription starting on April 21 and closing on April 25 (both days inclusive). On April 28, 2023, the basis for allocation will be finalised, and on May 2, 2023, the reimbursement process will begin. The stock will float on the NSE and the BSE on May 4th 2023, and the demat credits are anticipated to take place on May 3rd 2023. Following Avalon Technologies, Mankind Pharma will be the second mainboard IPO of FY24, and its success will be key in gauging the appetite for expensive IPOs.
Investors have two options for applying: through their current trading account or directly through their online banking account. Only the authorised list of self-certified syndicate banks (SCSB) can be used for this. In an ASBA application, the necessary amount is only debited at the time of allotment and is only temporarily stopped at the time of application. Investors may apply in the HNI/NII quota (above Rs2 lakh) or the retail quota (up to Rs 2 lakh per application). After pricing, minimum lot sizes will be known.
Financial Highlights of Mankind Pharma Ltd
The financial highlights for Mankind Pharma Ltd’s most recent three fiscal years are shown in the table below.
| Details | FY22 | FY21 | FY20 |
| Total Revenues | Rs7,977.58 cr | Rs6,385.38 cr | Rs5,975.65 cr |
| Revenue growth | 24.94% | 6.86% | – |
| Profit after tax (PAT) | Rs1,452.96 cr | Rs1,293.03 cr | Rs1,056.15 cr |
| PAT Margins | 18.21% | 20.25% | 17.67% |
| Total Borrowings | Rs868.03 cr | Rs234.53 cr | Rs126.92 cr |
| Return on Assets | 15.88% | 20.29% | 20.82% |
| Asset Turnover Ratio (X) | 0.87X | 1.00X | 1.18x |
What is GMP Mankind Pharma IPO
The grey market pricing (GMP) trading typically begins 4-5 days before the launch of the IPO and lasts until the listing day. We already have GMP data for the last five days for Mankind Pharma Ltd, which should provide a reasonable post-listing picture. The GMP is impacted by 2 things. First and foremost, the Nifty and Sensex levels as well as the general macro and IPO market circumstances have a significant impact on the GMP. Second, as a measure of investor fervour, the extent of IPO subscription across the retail and QIB categories also has a significant impact on the GMP.
Here, it’s important to keep in mind a little detail. The GMP is merely a well-liked informal price point and not an official price point. However, it has generally been found to be a reliable informal indicator of supply and demand for the IPO. As a result, it does provide a general indication of how the listing is likely to go and how the stock’s performance will be after the listing.
For the Mankind Pharma IPO for which the data is available, here is a brief description of GMP.
| Date | GMP |
| 9-May-2023 | Rs. 121 |
| 8-May-2023 | Rs. 140 |
| 7-May-2023 | Rs. 113 |
| 6-May-2023 | Rs. 113 |
| 5-May-2023 | Rs. 97 |
| 4-May-2023 | Rs. 103 |
| 3-May-2023 | Rs. 79 |
| 2-May-2023 | Rs. 82 |
| 1-May-2023 | Rs. 96 |
| 30-Apr-2023 | Rs. 88 |
| 29-Apr-2023 | Rs. 83 |
| 28-Apr-2023 | Rs. 84 |
| 27-Apr-2023 | Rs. 60 |
| 26-Apr-2023 | Rs. 28 |
| 25-Apr-2023 | Rs. 80 |
| 24-Apr-2023 | Rs. 90 |
| 23-Apr-2023 | Rs. 71 |
| 22-Apr-2023 | Rs. 71 |
| 21-Apr-2023 | Rs. 65 |
| 20-Apr-2023 | Rs. 74 |
| 19-Apr-2023 | Rs. 74 |
| 18-Apr-2023 | Rs. 95 |
| 17-Apr-2023 | Rs. 96 |
| 16-Apr-2023 | Rs. 75 |
| 15-Apr-2023 | Rs. 82 |
How Does The GMP Impact The IPO Listings?
The grey market premium aids in determining whether investors are interested in a particular IPO depending on whether it is positive or negative.
Similar to stock pricing, the supply and demand for a stock determines the grey market premium for an IPO. If fewer subscriptions are received for a particular IPO than the number of shares offered in the IPO, the GMP will be lower. On the other hand, if there are more subscribers than there are shares being sold in the IPO, the GMP will be higher.
How is GMP relevant?
1.Retail investors claim that GMP is a very reliable indicator of how well an IPO will do.
2.The Kostak rate is the price at which an IPO application could be sold off for a set amount, whether or not allocation is gained.
3.The GMP is what decides how interested investors are in an IPO.
4.The Grey Market Premium’s ability to estimate the listing price with accuracy, however, cannot be guaranteed. It is one of the instruments to use, though, before making an IPO investment.
5.The grey market still functions effectively today because the trades are honoured in the vast majority of circumstances.
What are Pharma Stock in India 2023-
The “pharmacy of the world” label has been obtained by India. Even during the COVID-19 epidemic, the pharmaceutical industry was crucial in guaranteeing the uninterrupted availability of medications around the world.
India is rated third globally in terms of pharmaceutical product output by volume and fourteenth globally in terms of value. India has a 20% share in the volume of generic drugs supplied globally, making it the largest supplier in the world. Additionally, the nation is a major producer of vaccines.Shares in pharmaceutical companies are known as pharma stocks. These businesses engage in a variety of business activities, including the production of vaccines, generic drugs, over-the-counter medications, active pharmaceutical ingredients/bulk drugs, biosimilars, and biologics. The pharmaceutical sector has switched its emphasis over time from volume play to value creation. By 2030, the industry is predicted to be worth $130 billion. This suggests that businesses should increase their production capabilities while getting ready to pay for R&D expenditures.
Government programmes like production-linked incentive schemes, which increase domestic manufacturing capacity and promote high-value goods throughout the global supply chain, also benefit the sector.All of these elements are enticing investors to consider pharmaceutical stocks.
Best Pharma Stock in India 2023-
1. Sun Pharmaceutical Industries Ltd
The largest pharmaceutical company in India, Sun Pharma, with a market value of more than Rs 2 lakh crore. Given its significant position, it ranks among the best pharmaceutical stocks. With a global revenue of more than $5.1 billion, it is the fourth-largest specialty generic pharmaceutical firm in the world.
It has developed a range of specialised medications with patent protection for international markets. Additionally, its product line also offers OTC and generic drugs. Your choice of Sun Pharma as the best pharmaceutical stock to purchase in India in 2023 may be based on the company’s wide geographic reach and variety of product offerings.
2.Divi’s Laboratories Ltd
The top manufacturer of APIs (active pharmaceutical ingredients) is this Hyderabad-based business. The company has invested 2,800 crores of rupees in capital expenditures at its current facilities, which are anticipated to support the company’s expansion over the next 12 to 24 months. Take notice, growth investors searching for the greatest pharmaceutical stocks.
3.Dr Reddy’s Laboratories Ltd
Investors seeking for pharmaceutical stocks to purchase ought to consider this business, which aims to crack the top 5 in India. Although the company’s API business is a major pillar, its portfolio also includes generic and branded generic drugs, biologics, and OTC products.
4.Cipla Ltd
It has become one of the top pharmaceutical stocks to purchase in 2023. It has a wide range of products, and the generics business it operates in India accounts for 19% of domestic pharmaceutical sales.
5.Biocon Ltd
Biocon is a biopharmaceutical business situated in Bangalore. In 1978, Kiran Mazumdar-Shaw started it. The company creates branded formulations, biosimilars, innovative biologics, and generic active pharmaceutical components. More than 120 nations around the world, including the US and Europe, sell its products.
6.Apollo Hospitals
Despite not being a pharmaceutical company, Apollo is India’s largest hospital network. It was founded in 1983 and has a significant presence throughout the healthcare ecosystem, including among others, hospitals, pharmacies, primary care, and diagnostic clinics. Apollo Hospital is now one of the top healthcare stocks as a result.
Investors can also search for more businesses like Zydus Lifesciences, Lupin, Abbott India, Alkem Laboratories, and Torrent Pharmaceuticals Ltd. while looking for the finest pharmaceutical stocks to buy.
Which is number 1 Pharma Company?
Sun Pharmaceutical Industries Ltd
As of March 31, 2023, Sun Pharmaceutical Industries Ltd. is the largest pharmaceutical firm in India. For the fiscal year that ended in March 2022 (FY2022), the business recorded revenues of $5,235 million, an increase of 15.4% over FY2021.
Who are the 3 big in Pharma?
The “Big Three”—AmerisourceBergen, Cardinal Health, and McKesson—control the wholesale (primary care) and generic drug distribution markets, and these businesses are also distributing more and more speciality medications.
What are the top 5 Pharmaceutical Companies ?
displaying 10 of 25 businesses. According to market capitalization as of March 31, 2023, Johnson & Johnson, Eli Lilly and Co., AbbVie Inc., Merck & Co. Inc., and Pfizer Inc. are the top 5 pharmaceutical corporations in the US.
Which Pharma Company gives you the Highest Salary?
Some of the top pharmaceutical firms in India are Dr. Reddy’s Laboratories, Sun Pharmaceuticals, Aurobindo, Mylan Labs, Laurus Laboratories, NATCO Pharma, Divis Labs, Gland Pharma, Santha Biotech, Indian Immunological, Cadila, and Aventis.
Benefits of Investing in Pharma Stock 2023
1. Growth plus value
Pharma stocks are renowned for being both growth and value companies, bringing stability and profits. Given the rise in non-communicable diseases including diabetes and hypertension as well as chronic diseases like these, the sector is expected to expand due to increased demand in the domestic market. Many pharmaceutical firms took action in 2022 to increase their field capacity in the domestic market, which is anticipated to increase penetration during the next two to three years.
2.High profit margin
The average industry profit margin is high, and the majority of businesses also have substantial levels of free cash flow. Additionally, pharmaceutical firms have a history of paying dividends on time. When these elements are considered collectively, pharmaceutical stock investors would see larger returns.
3. Diversification and defensive
Because their revenues are unrelated to economic success, pharmaceutical companies are renowned for being defensive investments. Simply put, individuals will continue to purchase the necessary medications even in a recession. Pharma businesses are concentrating on balancing local and export market revenues, despite the possibility that pricing pressure, particularly in the important US market, could have an impact. The protective character of pharmaceutical stocks makes them a potential asset for the portfolio.